2023 Genitourinary Cancers Symposium Meeting Reporter | Supplements and Featured Publications

March 10, 2023

The combination of cabozantinib and atezolizumab elicited responses in patients with non–clear cell renal cell carcinoma, according to extended follow-up data from the phase 1b COSMIC-021 trial.

March 09, 2023

The progression-free survival benefit associated with the combination of nivolumab plus cabozantinib compared with sunitinib was largely independent of PD-L1 and c-MET status in previously untreated patients with advanced or metastatic renal cell carcinoma.

February 19, 2023

The combination of nivolumab and cabozantinib produced prolonged progression-free survival and higher response rates compared with sunitinib alone as frontline therapy in patients with advanced renal cell carcinoma, regardless of International Metastatic RCC Database Consortium risk status.

February 19, 2023

89Zr-DFO-girentuximab demonstrated sensitivity and specificity thresholds that were exceeded by 3 independent readers for PET/CT imaging of clear cell renal cell carcinoma, according to findings from the phase 3 ZIRCON study.

February 18, 2023

The combination of frontline cabozantinib, nivolumab, and ipilimumab led to a greater improvement in progression-free survival in patients with intermediate- vs poor-risk advanced renal cell carcinoma.

February 18, 2023

Treatment with cabozantinib elicited responses in patients with locally advanced or metastatic renal cell carcinoma with a clear-cell component who had progressed after first-line treatment with checkpoint inhibitor–based combination therapy.

February 18, 2023

At extended follow-up, nivolumab monotherapy showed improved disease-free survival, non-urothelial tract recurrence-free survival, and disease-specific survival vs placebo in patients with resected, high-risk muscle-invasive urothelial carcinoma.

February 18, 2023

Pembrolizumab monotherapy led notable antitumor activity with manageable toxicity in patients with Bacillus Calmette-Guérin–unresponsive, papillary high-risk non–muscle-invasive bladder cancer

February 16, 2023

The final prespecified overall survival analysis of PROpel showed that the combination of abiraterone acetate plus olaparib sustained a trend toward improved efficacy vs standard-of-care abiraterone in patients with metastatic castration-resistant prostate cancer.

February 16, 2023

Talazoparib plus enzalutamide generated a statistically significant and clinically meaningful improvement in radiographic progression-free survival vs placebo plus enzalutamide as first-line treatment for patients with metastatic castration-resistant prostate cancer, irrespective of homologous recombination repair status.